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Telomere length is maintained by two known mechanisms, activation of telomerase or alternative lengthening of telomeres (ALT).
The ALT pathway is more commonly activated in tumours of mesenchymal origin, although the mechanisms involved in the decision
of a cell to activate either telomerase or ALT are unknown at present and no molecular markers exist to define the ALT phenotype.
We have previously shown an association between chromatin remodelling, telomerase gene expression and ALT in cell line models.
Here, we evaluate these findings and investigate their prognostic significance in a panel of liposarcoma tissue samples to understand
the biology underlying the ALT phenotype. Liposarcoma samples were split into three groups: telomerase positive (Telþ); ALT
positive; ALT /Tel . Differences in telomerase gene expression were evident between the groups with increased expression of hTR
in ALT and Telþ compared to ALT /Tel  samples and increased hTERT in Telþ samples only. Investigation of a small panel of
chromatin modifications revealed significantly increased binding of acetyl H3 in association with hTR expression. We confirm that the
presence of the ALT phenotype is associated with poor prognosis and in addition, for the first time, we show a direct association
between hTR expression and poor prognosis in liposarcoma patients.
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The activity of the ribonucleoprotein complex telomerase is reliant
on the expression of both hTR and hTERT genes, the regulation of
which is tightly coordinated on multiple levels by transcriptional,
post-transcriptional (Zhao et al, 2000, 2003, 2005; Cong et al, 2002;
Anderson et al, 2006; Bilsland et al, 2006) and epigenetic
mechanisms (Atkinson et al, 2005; Serakinci et al, 2006). In most
normal somatic cells, telomerase is inactivated following develop-
ment so that telomeres shorten after each round of replication
until they reach a critical length, signalling senescence or cell
death. The majority of human tumours reactivate telomerase to
maintain telomere length allowing them to bypass senescence and
continue to proliferate. However, telomere length maintenance can
also be achieved in some tumour types in the absence of
telomerase activity through an alternative recombination-based
mechanism termed ALT (alternative lengthening of telomeres)
(Bryan et al, 1995, 1997). Alternative lengthening of telomeres is
characterised phenotypically by heterogeneous telomeres, ranging
from less than 3kb to more than 50kb in length (Henson et al,
2002), and the presence of ALT-associated promyelocytic leukae-
mia (PML) bodies (APBs), which contain telomeric DNA and the
telomere binding proteins, TRF1 and TRF2, in addition to several
other proteins associated with DNA recombination and repair,
including RAD51 and RAD52 (Yeager et al, 1999; Henson et al,
2002).
The ALT pathway is detected in some tumours of epithelial
origin, including carcinomas of the breast, lung and kidney;
however, it is found at higher frequency in tumours of
mesenchymal origin, such as liposarcomas, osteosarcomas and
glioblastomas (Henson et al, 2002). This is thought to be due to
tighter repression of telomerase expression in mesenchymal
tissues, which have a slower cell turnover and less telomere
shortening than many epithelial tissues (Henson et al, 2002).
Several studies have highlighted an association of the ALT
phenotype with sarcomas that have complex karyotypes with
many chromosomal losses and gains and evidence of anaphase
bridge formation, more consistent with chromosomal instability,
while those that have generally more simple karyotypes, including
fusion genes created from chromosomal translocations, are
associated with telomerase activity (Montgomery et al, 2004;
Ulaner et al, 2004).
Liposarcomas are among the most common soft tissue sarcomas
forming around 20% of all mesenchymal tumours (Sandberg,
2004). They are a diverse group of mesenchymal malignancies that
show multiple telomere maintenance mechanisms (TMMs) with
telomerase activity and the ALT phenotype detected in a similar
number of cases (Johnson et al, 2005; Costa et al, 2006).
Alternative lengthening of telomeres is more frequent in well-
differentiated and dedifferentiated forms (Costa et al, 2006), which
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sshow complex karyotypic rearrangements including supernumerary
ring, giant chromosome formation and amplification (Sandberg,
2004), while telomerase activity is more frequent in myxoid
forms (Costa et al, 2006) characterised by the t(12;16)(q13;p11)
translocation (Sandberg, 2004). In addition, a significant propor-
tion appears to show no evidence of any known TMM (Johnson
et al, 2005; Costa et al, 2006). This complexity makes liposarcoma
a good model system to investigate the regulation of TMMs.
The presence of any TMM, in comparison to tumours that
express neither telomerase nor ALT, is associated with poor
prognosis in a number of tumours of mesenchymal origin
(Sanders et al, 2004; Costa et al, 2006). In osteosarcoma,
telomerase expression is associated with shorter progression-free
survival (Sanders et al, 2004), while in liposarcoma the ALT
phenotype is associated with a lower survival rate (Costa et al,
2006). This appears to be tissue specific, as the presence of the ALT
phenotype in patients with glioblastoma multiforme was asso-
ciated with a longer survival rate than those with telomerase
activity or no TMM (Hakin-Smith et al, 2003).
The molecular mechanisms involved in the decision to activate
either telomerase or the ALT pathway within a particular cell type
are so far unknown. As mentioned above, the presence of APBs is a
defining characteristic of the ALT phenotype. A recent study
showed the requirement of PML, TRF1, TRF2, TIN2, RAP1 and the
MRN complex proteins MRE11, RAD50 and NBS1 for APB
formation in ALT cells. The close association of APB formation
with ALT highlights these genes as candidate markers or regulators
of the ALT pathway (Jiang et al, 2007); however, the mechanisms
of regulation remain to be fully determined. We have recently
shown that chromatin remodelling at the telomerase gene
promoters is associated with a lack of expression of hTR and
hTERT in some ALT cell lines, highlighting one potential
mechanism for regulating the activation of ALT or telomerase
(Atkinson et al, 2005). Here, we analyse telomerase gene
expression and the association of a small panel of chromatin
modifications, with expression of these genes in liposarcoma
samples with relation to TMM and patient prognosis, to investigate
the molecular regulation of the ALT phenotype in tumour tissue.
The identification of molecular regulators or markers of the ALT
pathway will be useful not only as prognostic indicators of patient
survival but may also highlight areas for therapeutic intervention
to treat these tumours more effectively.
MATERIALS AND METHODS
Study population
Samples from 27 liposarcomas, all from adult patients treated with
curative intent at the Istituto Nazionale Tumori of Milan from
December 1986 to November 2003 were available for TMM,
telomerase gene expression and chromatin modification analyses.
These specimens represent a subset randomly selected from a
larger case series already characterised for TMM (Costa et al,
2006). There were 13 women and 14 men, with a median age of 58
years (range, 38–91). Four patients presented at Istituto Nazionale
Tumori of Milan with primary disease and 23 with recurrent
tumours (22 recurrences and 1 metastasis), and they underwent
different surgical procedures according to disease presentation.
Tumour characteristics in terms of histology and grade are
reported in Table 1. Postoperative treatment was given when there
were clinical grounds for concluding that a high risk of recurrence
existed: eight patients were submitted to radiotherapy, two to
chemotherapy, and one to radiochemotherapy according to the
treatment protocols of the multidisciplinary Istituto Nazionale
Tumori of Milan Soft Tissue Sarcoma Group. The median follow-up
for the entire group as of December 2006 was 108 months. During
the follow-up period, 12 patients died of liposarcoma-related
causes, 5 were alive with disease and 7 were disease free. Three
patients were lost to follow-up.
All patients provided written informed consent to donate the
tissue that was left over after diagnostic procedures were
completed to the Istituto Nazionale Tumori of Milan.
Detection of APBs and telomerase activity
Tumour tissue was sampled by a pathologist at the time of surgery
and fresh-frozen. Detection of APBs by combined PML immuno-
fluorescence and telomere fluorescence in situ hybridisation
(FISH) and telomerase activity by the telomeric-repeat amplifica-
tion protocol (Kim et al, 1994) with the TRAPeze kit (Intergen
Company, Oxford, UK) were carried out as outlined in Costa et al
(2006).
Sample preparation for RNA extraction and ChIP assay
Frozen tissue samples varying in size from 50 to 120mg were
disrupted into small pieces with liquid nitrogen and a mortar and
pestle and then split in half for use in chromatin immunopreci-
pitation (ChIP) assay and RNA extraction for telomerase gene
expression analysis.
Expression analysis
Further disruption of the tissue was carried out in RA1 buffer plus
b-mercaptoethanol (Nucleospin II RNA extraction kit, Macherey-
Nagel, Du ¨ren, Germany) in a Ribolyser (Hybaid, Waltham, MA,
USA) at a setting of 5.5 for 5 10s pulses with 30s pauses between.
Samples were then passed through an 18-gauge needle to shear
genomic DNA. RNA was extracted using the Nucleospin II RNA
extraction kit (Macherey-Nagel) following the manufacturer’s
Table 1 Main tumour characteristics
Tumour Grade
Histological
subtype TMM
hTR
expression
hTERT
wild-type
expression
S1 1 WD ALT Tel  Low No
S2 1 WD ALT Tel  Low No
S3 2 WD ALT Tel  High No
S4 1 WD ALT Tel  High No
S5 1 WD ALT Tel  High No
S6 2 WD ALT Tel  Low No
S7 1 Myx ALT Tel  High No
S8 1 WD ALT Tel  Low No
S9 1 WD ALT Tel  Low No
S10 1 DD ALT+ No result No
S11 1 DD ALT+ High No
S12 3 DD ALT+ High No
S13 3 DD ALT+ High No
S14 3 RC ALT+ High No
S15 2 DD ALT+ Low Yes
S16 3 DD ALT+ High No
S17 3 DD ALT+ High No
S18 2 Myx ALT+ Low No
S19 1 RC ALT+ High No
S20 2 Myx Tel+ High Yes
S21 3 Myx Tel+ High Yes
S22 2 DD Tel+ High No
S23 1 RC Tel+ Low No
S24 2 RC Tel+ High Yes
S25 2 DD Tel+ High Yes
S26 1 Myx Tel+ High Yes
S27 2 RC Tel+ High Yes
DD¼dedifferentiated; Myx¼usual myxoid; RC¼round-cell myxoid; WD¼well
differentiated. Cutoff for low or high hTR expression was taken as the mean of all
samples minus two standard errors.
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(Q-PCR) as described previously (Atkinson et al, 2005) and taken
as a percentage of the riboprotein S15 (primers (RETROscript kit,
Ambion) S15 Forward TTCCGCAAGTTCACCTACC, S15 Reverse
CGGGCCGGCCATGCTTTACG). hTERT expression was analysed
by semiQ-PCR using primers designed to detect the four main
hTERT splice variants (Atkinson et al, 2005). Samples were
adjusted for S15 expression prior to splice variant PCR, and total
hTERT levels were taken as the sum of all splice variant products
quantified using the Agilent Bioanalyser as described previously
(Keith and Hoare, 2004).
Chromatin immunoprecipitation
Chromatin immunoprecipitation assays were carried out using the
Upstate Biotechnologies protocol as described previously (Atkinson
et al, 2005), with some modifications for tissue handling
adapted from Farnham’s ChIP protocol for tissues (http://
genomics.ucdavis. edu/farnham/). Half of the disrupted tumour
sample was fixed in PBS containing 1% formaldehyde. After
10min, 0.125 M glycine was added to quench the formaldehyde and
stop the cross-linking. Tissue was rinsed in cold PBS and further
disrupted in a dounce homogeniser. Cells were lysed in Farnham’s
cell lysis buffer (5mM PIPES, pH 8.0; 85mM KCl; 0.5% NP40; 1mM
PMSF; 2mgml
 1 aprotonin; 1mgml
 1 pepstatin) using 500ml per
50mg tissue, then passed through a series of needles (18–25
gauge) to release the nuclei. Samples were resuspended in SDS lysis
buffer (Upstate Biotechnologies, Watford, UK) with protease
inhibitors (400ml buffer per 50mg tissue) and incubated on ice
for 90min. The remainder of the protocol was carried out as
described (Atkinson et al, 2005); however, no DNA purification
was required.
Quantitative PCR
Products from ChIP assays were analysed by Q-PCR as described
previously (Atkinson et al, 2005). Data are presented as a
percentage of input following subtraction of the background
pulled down with the no antibody control.
Antibodies
Antibodies used were AcH3, AcH4 and TriMeK20 (all Upstate
Biotechnologies) and TriMeK9 (Abcam, Cambridge, UK). Tissue
(13–25mg) was required per antibody.
Data analysis
Criteria used to define the presence of telomerase and ALT
phenoypes were previously detailed (Costa et al, 2006). The cutoff
to discriminate between low and high hTR expression was defined
as 97% of S15 expression (mean of all samples minus two standard
errors). hTERT-positive cases were defined as those expressing the
wild-type variant. In vitro measurements were performed by
personnel blinded to patient data and clinical outcome, whereas
clinical data were collected by personnel blinded to in vitro data.
Kruskal–Wallis, Mann–Whitney and w
2 tests were used to assess
differences in the distribution of data categorised according to the
investigated features. The clinical end point of this study was
cause-specific mortality, and the time of its occurrence was
computed from the date of first diagnosis to the time of death or
censored at the date of the last recorded follow-up for living
patients or for those who died from liposarcoma-unrelated
conditions. Survival analysis was carried out with Cox regression
models after checking for the proportional hazard assumption.
SAS software (SAS Institutes Inc., Cary, NC, USA) was used for
statistical calculations. All P-values were two-sided; Po0.05 was
considered to be statistically significant.
RESULTS
How does telomerase gene expression relate to the ALT
phenotype?
A total of 27 liposarcoma tissue samples were collected from 27
different patients and evaluated for telomerase activity using the
TRAP assay and for the ALT phenotype using immunofluores-
cence/FISH to detect ALT-associated PML bodies. The samples
were then split into three groups depending on TMM status:
telomerase positive (Telþ); ALT positive; both Tel /ALT .T o
explore the molecular mechanisms underlying the morphological
determination of the ALT phenotype, we analysed expression of
hTR and hTERT at the RNA level.
hTR expression, normalised to expression of the riboprotein
S15, was determined by Q-PCR and expressed as a percentage of
S15 (Figure 1A). All of the liposarcoma samples evaluated in this
study expressed hTR to varying degrees; however, significant
differences in expression were found within the three groups
(P¼0.05). Samples that were negative for both telomerase and
ALT had mostly low-level expression with a median level of 48% of
S15 expression (range 20–333%), while those that were Telþ had
an even distribution of expression with a median level of 242%
(range 31–562% with one outlier at 1783%). Those samples
expressing the ALT phenotype, on the other hand, appeared to
have a higher distribution of expression, although the median
value of 199% did not reflect this (range 71–653% with one outlier
at 3575%).
hTERT expression evaluated by semi-Q-PCR is shown in
Figure 1B. The majority of liposarcoma samples, which were
negative for both telomerase and ALT or expressed the ALT
phenotype, had little or no total hTERT expression. The median
level for both of these groups was 0ngml
 1. Conversely, the
majority of samples that were Telþ expressed significantly higher
levels of hTERT in comparison to the other groups, with a median
level of 9.4ngml
 1. TERT expression is known to be regulated by
differential splicing; therefore, we investigated the expression
pattern of the four main splice variants of hTERT (Figure 1C).
Little expression of any of the splice variants was detected in the
samples, which were negative for both telomerase and ALT. The
inactive beta variant was detected in two of these samples and the
active wild-type variant was not detected at all. Likewise, for
samples expressing the ALT phenotype, three samples expressed
the inactive beta variant and only one sample expressed the active
wild-type variant. It is of interest to note that this sample is the
only one in which the dominant-negative alpha variant is detected
and it is one of only two ALT samples expressing no hTR. In
contrast, the active wild-type variant could be detected in the
majority of the Telþ samples with the exception of samples 22
and 23. Lack of the wild-type variant in these samples may reflect
differences in sensitivity between the TRAP assay and the splice
variant PCR.
Table 2 provides a summary of the expression data generated for
the liposarcoma samples separated by phenotype and expression,
where hTRþ is taken as over 97% of S15 expression (mean of all
samples minus two standard errors) and hTERTþ is taken as
expressing the wild-type splice variant. A statistically significant
(P¼0.004) association was observed between the absence or
presence of TMMs and telomerase gene expression. Telomerase
enzymatic activity is dependent on expression of both hTR and
hTERT; therefore, it is interesting to note that the only samples
positive for both hTR and hTERT expression lie within the Telþ
group. The fact that two other samples lie within the Telþ group,
although they appear to be negative for hTERT or both hTERT and
hTR, could reflect differences in assay sensitivity rather than
phenotype, as mentioned previously. The majority of samples
expressing the ALT phenotype, on the other hand, express only
hTR, with the exception of one sample that expresses hTERT alone
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sand two more that have neither hTERT nor hTR expression. A high
level of hTR and little or no hTERT expression in association with
the ALT phenotype has been shown previously in cell line models
(Hoare et al, 2001; Atkinson et al, 2005). Finally, samples lacking
both telomerase expression and ALT are negative for hTR and
hTERT or express only hTR.
How does the chromatin landscape relate to telomerase
gene expression in liposarcoma?
It is well known that gene expression can be controlled at the level
of chromatin and we have previously shown that telomerase gene
expression is subject to epigenetic regulation by chromatin
remodelling in cell line models. To determine whether modifica-
tion of the chromatin landscape bears any relation to telomerase
gene expression in liposarcoma, we used chromatin immunopre-
cipitation to study the association of a small panel of histone
modifications with the telomerase gene promoters. Samples were
grouped according to levels of hTR expression or by the presence
or absence of the hTERT wild-type splice variant. The association
of two modifications related to active gene expression, acetyl
histone H3 and acetyl histone H4, and two modifications related to
gene repression and the heterochromatic state, tri-methyl lysine 9
of histone H3 and tri-methyl lysine 20 of histone H4, with the hTR
and hTERT promoters were investigated within these expression
groups (Figures 2 and 3, respectively).
The data in Figure 2 show a relationship between hTR
expression and acetylation of histones H3 and H4. Association of
acetyl H3 (Figure 2A) with the hTR promoter is significantly
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Figure 1 Telomerase gene expression in liposarcoma samples. (A) hTR expression taken as a percentage of the riboprotein S15; (B) total hTERT
expression in ng per ml. The grey box defines 25 and 75% quartiles, while error bars represent the first and 99th percentiles of the distribution. Dots
represent outliers and the black line defines the median of the distribution. P-values were calculated using the Kruskal–Wallis test, which tests the likelihood
of all medians being the same. (C) Four major hTERT splice variant PCR products were quantified using the Agilent Bioanalyser.
Table 2 Summary of telomerase gene expression in relation to ALT
phenotype or telomerase status
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Figure 2 Chromatin modifications associated with low and high hTR
expressing liposarcoma samples represented as a percentage of input
chromatin. (A) Association of acetyl histone H3; (B) association of acetyl
histone H4; (C) association of tri-methyl K9 of H3; (D) association of tri-
methyl K20 of H4. The grey box defines 25 and 75% quartiles, while error
bars represent the first and 99th percentiles of the distribution. Dots
represent outliers and the black line defines the median of the distribution.
P-values were calculated using the Mann–Whitney test, which tests the
likelihood of all medians being the same.
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sincreased as a function of hTR expression (median levels of 5.5 and
20.8% of input for low and high expressors, respectively;
P¼0.001), while the increase in association of acetyl H4 with the
hTR promoter in high expressors compared to low expressors
(median levels of 19.4 and 6.3% of input, respectively) did not
reach significance (P¼0.28). In the case of the negative modifica-
tions, no significant differences in association were seen between
high and low expressing samples (Figure 2C and D). These results
suggest that hTR expression in these liposarcoma samples is
associated with positively acting histone modifications and that the
negative modifications we have chosen for this study bear no
relation to hTR gene expression.
The relationship between binding of these chromatin modifica-
tions and hTERT expression is less obvious, as there are no
significant differences between those samples expressing the wild-
type variant and those that do not (Figure 3). Although the small
differences that we do see in association of these modifications
appear uninformative and are not statistically significant, the
actual levels of hTERT expression are very low with normal levels
of 1–30 copies of the gene per cell (Yi et al, 2001); therefore, these
slight differences in chromatin occupancy could be biologically
significant. It could be that for hTERT the lack of negatively acting
chromatin modifications is more important than the presence of
positive modifications, at least of those chosen for this study.
Does chromatin modification at the telomerase gene
promoters distinguish between the differential expression
of the three phenotypes?
The results of the previous section suggest that while acetylation of
histones at the hTR promoter was related to hTR expression levels,
no clear pattern of regulation could be seen for hTERT. To further
study the mechanism of regulation of the TMM phenotype, we next
looked at the potential of these chromatin modifications as
molecular markers to distinguish among the three phenotype
groups within our liposarcoma samples. Samples were grouped
according to telomerase status or ALT phenotype following
chromatin immunoprecipitation as previously.
Figure 4 shows association of chromatin modifications at the
hTR promoter within the three phenotype groups. Although none
of the differences in median levels reached statistical significance,
clear trends were seen in the association of positively and
negatively acting chromatin modifications across the three
phenotype groups. Consistent with expected results, the highest
levels of the positively acting marks, acetylation of H3 (Figure 4A)
and H4 (Figure 4B), were found in Telþ samples (median levels of
32.3 and 23.7% of input, respectively), which also have the highest
median levels of hTR expression. No clear association was
observed between the levels of the negatively acting marks, tri-
methyl K9 (Figure 4C) and tri-methyl K20 (Figure 4D) and the
distinct TMM subsets. As was the case with expression levels for
hTR, levels of acetylation in those samples expressing the ALT
phenotype lie somewhere between those those were either positive
for telomerase or negative for both telomerase and ALT (Figure 4A
and B).
In agreement with hTERT expression, the results for association
with the hTERT promoter are not so clear and no obvious
relationships between binding of the chosen chromatin modifica-
tions and telomerase status or ALT phenotype were found (data
not shown).
How do telomerase gene expression and the ALT
phenotype relate to clinical outcome in patients with
liposarcoma?
To determine whether telomerase gene expression and the ALT
phenotype would bear any relationship to patient survival, the
clinical outcome was evaluated at the median time of follow-up,
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Figure 3 Chromatin modifications associated with liposarcoma samples
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likelihood of all medians being the same.
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swhich in the present series was 9 years. The presence or absence of
TMMs segregated liposarcoma patients into distinct prognostic
subsets (Figure 5): in fact, 9-year probability of survival was 75%
for the 9 patients with ALT /Tel  tumours, 51% for the 8 patients
with telomerase-positive tumours and only 25% for the 10 patients
with ALT-positive tumours. Specifically, compared to patients with
ALT-positive tumours, those with ALT /Tel  or with telomerase-
positive tumours had a 0.19-fold (95% confidence limit (CL),
0.04–0.94, P¼0.042) and a 0.38-fold (95% CL, 0.10–1.53, P¼0.17)
hazard of death. However, when adjusted for tumour grade, the
lower hazard of death for patients with ALT /Tel  tumours vs
those with ALT-positive tumours became only suggestive of
statistical significance (hazard ratio (HR), 0.15; 95% CL, 0.016–
1.48, P¼0.09).
Tumour grade and the histological subtype of the liposarcoma
samples are important considerations that should be taken into
account when looking at the relationship between telomerase gene
expression, TMM and clinical outcome. Consistent with previous
results (Costa et al, 2006), clinical outcome and TMM correlate
with histological subtype. Those in ALT or Tel-positive groups,
which have a poorer prognosis, have an increased incidence of the
more aggressive liposarcoma subtypes, dedifferentiated or usual
myxoid and round-cell myxoid subtypes, respectively, while the
well-differentiated tumours were the most abundant subtype
within the ALT /Tel  group, which has the best prognosis
(summarised in Table 3). Similarly, taking into account tumour
grade, a statistically significant association (P¼0.016; w
2 test) was
observed between TMM and grade. Grade 1 tumours were mainly
represented by ALT /Tel  cases (7/12), grade 2 by Tel-positive
(5/9) and grade 3 by ALT-positive (5/6) (reported in Table 1).
The results of this study suggest that levels of telomerase gene
expression can distinguish among the three TMM phenotype
groups; therefore, the relationship of hTR and hTERT expression
to prognosis was considered in two ways, by taking the
liposarcoma samples as one whole group or by subdividing this
large group by the presence or absence of the ALT phenotype.
Firstly, we looked at the prognostic significance of hTR and hTERT
in all liposarcoma samples. When considered as dichotomous
variables, using the mean of all samples minus two standard errors
(97% of S15 expression), as a cutoff to define low or high hTR
expression, or any detectable level of wild-type variant for hTERT,
no association was observed between these two variables and
survival (HR and 95% CLs for hTR, 1.65 and 0.44–6.24, P¼0.46;
HR and 95% CL for hTERT, 1.57 and 0.45–5.47, P¼0.48).
Conversely, when hTR abundance was considered as a continuous
variable, a trend in favour of a worse prognosis for patients whose
tumours expressed the higher levels was observed (P¼0.067,
Figure 6), which reached statistical significance after logarithmic
transformation (HR and 95% CL, 1.65 and 1.03–2.65, P¼0.036).
In contrast, hTERT expression failed to provide prognostic
information, even when considered as a continuous variable.
We next looked at the prognostic significance of hTR and
hTERT adjusted for the most important variable in this series, the
presence or absence of ALT. While hTERT expression gave no
prognostic information, hTR expression had some prognostic
significance within ALT  (HR and 95% CL, 2.15 and 0.97–6.52,
P¼0.058), but not within ALTþ subsets.
The association between high hTR expression and poor
prognosis led us to investigate any relationship between hTR
expression and histological subtype or tumour grade. When
considered as a dichotomous variable, using the mean of all
samples minus two standard errors as the cutoff, no significant
association was shown between hTR expression and histological
subtype or tumour grade of the liposarcoma samples. However,
when the median expression levels were considered, we found a
trend in association, with the lowest hTR expression in those
tumours of the well-differentiated subtype compared to the other
more aggressive subtypes (summarised in Table 3). Similarly, a
significantly higher hTR expression (P¼0.0136; Kruskal–Wallis
test) was observed in grade 3 tumours (median value, 601)
compared to grade 2 (median value, 116) or grade 1 tumours
(median value, 100).
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Figure 5 Overall survival as a function of TMM. Comparison between
patients with ALT /Tel  tumours and those with telomerase-positive or
ALT tumours.
Table 3 Summary of histological subtype in relation to ALT phenotype
or telomerase status and hTR expression
Well
differentiated
Usual
myxoid
Round-cell
myxoid Dedifferentiated
ALT /
Tel 
810 0
ALT+ 0 1 2 7
Tel+ 0 3 3 2
hTR %
S15
48
(20–232)
212
(96–562)
271
(31–653)
393
(71–3575)
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Figure 6 Overall survival as a function hTR expression. Comparison
among patients with tumours expressing low, intermediate and high hTR
levels. High level of telomerase RNA classes were defined on the basis of its
frequency distribution, using the first and the third quartiles as cutoff values.
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ALT phenotype and high levels of hTR expression are singly
associated with poor prognosis in liposarcoma patients.
DISCUSSION
In this study, we sought to investigate the mechanisms regulating
the ALT phenotype in liposarcoma tissue samples, with specific
emphasis on telomerase gene regulation, to determine how the
morphological definition of ALT relates to the underlying biology
and clinical outcome. Significant differences in the expression of
hTR were found among the three phenotype groups, with samples
positive for telomerase or ALT having higher expression levels
than those that were negative for both telomerase and ALT.
Expression of hTERT, on the other hand, was significantly
increased only in Telþ samples.
Liposarcoma samples were initially separated according to their
TMM using telomerase activity and the presence or absence of
APBs. At present, we have little indication of how these TMMs are
regulated at the molecular level to determine which is activated in
particular tumour types. We have previously shown in cell line
models that regulation of telomerase gene expression is subject to
control at the epigenetic level. Methylation of CpG islands within
the hTR promoter in several ALT cell lines was associated with
gene repression (Hoare et al, 2001), while remodelling of the
chromatin environment in the promoters of both hTR and hTERT
was associated with differential gene expression in Telþ or ALT
positive tumour cell lines and normal cell line controls (Atkinson
et al, 2005) and repression in human mesenchymal stem cells
(Serakinci et al, 2006). Furthermore, treatment of Tel  cell lines
with the histone deacetylase inhibitor Trichostatin A and the
demethylating agent 5-aza 20deoxycytidine induced expression of
hTR and hTERT, consistent with decreased methylation and
increased association of acetylated histones at these gene
promoters (Atkinson et al, 2005; Serakinci et al, 2006). To evaluate
these cell line data in clinical samples, we investigated chromatin
remodelling in liposarcoma tissue samples using a limited panel of
histone modifications associated with gene activation and repres-
sion. An increased binding of positively acting modifications,
acetylation of histone H3 and histone H4, was shown in association
with higher levels of hTR expression, while no significant
differences were shown in association with hTERT expression. In
addition, no significant alterations in the binding of the negatively
acting modifications, tri-methyl lysine 9 of histone H3 and tri-
methyl lysine 20 of histone H4, at the telomerase gene promoters
were associated with either hTR or hTERT expression. The
association between histone acetylation and hTR expression has
been shown previously in cell line models; however, this is the first
time that the correlation between histone modification and gene
expression has been demonstrated in clinical samples.
It has been shown that APBs are not always associated with the
ALT phenotype (Fasching et al, 2005) and although candidate
genes have been suggested (Jiang et al, 2007), no molecular
markers for the detection of ALT have yet been confirmed.
Previous work in cell line models highlighted an association of tri-
methyl K20 of histone H4 with both telomerase gene promoters in
ALT cell lines, suggesting that chromatin modifications may have
potential as novel markers of the ALT phenotype (Atkinson et al,
2005). We investigated the potential for our limited panel of
chromatin modifications, in association with the telomerase gene
promoters, to distinguish among the three phenotype groups.
Although no significant differences in chromatin remodelling were
found among the three groups, trends of association were shown
with acetyl H3 and H4 at the hTR promoter. Perhaps by using a
more extensive panel of modifications or a genome-wide screen,
other candidate molecular markers for the ALT phenotype could
be uncovered in future experiments.
While we found no significant differences among the three TMM
phenotype groups using the limited panel of chromatin modifica-
tions studied, differences were highlighted in telomerase gene
expression itself. We further investigated expression of hTR and
hTERT in relation to histological subtype, tumour grade and
patient survival as potential prognostic indicators in liposarcoma.
While hTERT expression was devoid of prognostic significance,
statistical analysis highlighted a trend in favour of worse prognosis
for patients with tumours expressing high levels of hTR. No
significant association was found between hTR abundance and
histological subtype or tumour grade when hTR expression was
considered as a dichotomous variable; however, a trend in
association of high hTR with the more aggressive subtypes and
significant association of high hTR with grade 3 tumours was
highlighted when median expression levels of hTR were consi-
dered. To our knowledge, this is the first time that such an
association between hTR expression and poor prognosis for
patients with liposarcoma has been documented.
Evidence is accumulating in support of the relationship between
telomerase gene expression, TMM and prognosis. It has been
shown in a number of mesenchymal tumour types that the
presence of any TMM is predictive of a poorer outcome in patients
(Ulaner et al, 2003; Sanders et al, 2004; Costa et al, 2006). The
statistical analysis of our patient material with relation to TMM
showed that patients with tumours expressing the ALT phenotype
had the lowest survival rate at follow-up. Furthermore, those
patients whose tumours neither expressed telomerase nor ALT had
the highest survival rate with a lower HR for death than those
expressing telomerase or the ALT phenotype, although this was
only suggestive of significance when adjusted for tumour grade.
Consistent with previously published results (Costa et al, 2006),
the more aggressive histological subtypes, dedifferentiated or
normal-myxoid and round-cell myxoid, were found within ALT or
Telþ groups, respectively, while the least aggressive well-
differentiated liposarcomas were all within the ALT /Tel  group.
Similarly, the highest proportion of grade 3 tumours were found
within the ALT group and the majority of Telþ tumours were
grade 2, while those that were ALT /Tel  were mostly of the least
aggressive grade 1. The association of the ALT phenotype with
clinical aggressiveness has been shown previously for liposarcoma
(Costa et al, 2006); however, the prognostic significance of ALT
appears to be tissue and tumour type-specific. In osteosarcoma,
hTERT is a predictive indicator of worse prognosis, with a trend in
favour of shorter progression-free survival in patients whose
tumours expressed telomerase rather than ALT (Sanders et al,
2004), while in glioblastoma multiforme the presence of ALT is
actually indicative of a better prognosis (Hakin-Smith et al, 2003).
The correlation between TMM, telomerase gene expression and the
various tissue-specific clinical outcomes may reflect the underlying
complexity of telomere biology in different tumour types and
certainly is of great importance to understanding telomere
maintenance and telomerase regulation.
As both expression of the ALT phenotype and high levels of hTR
were predictive of poor prognosis as individual factors, we also
investigated the prognostic significance of hTR expression as a
function of ALT presence. While hTR expression held no
prognostic significance within the ALT expressing subgroup, there
was a trend in favour of a worse prognosis for patients with ALT 
tumours expressing high levels of hTR.
From the results of our study and consistent with previous
results (Costa et al, 2006), the ALT phenotype is a strong predictor
of poor prognosis in liposarcoma; however, we have also shown a
novel direct association between high levels of telomerase RNA
gene expression and poor prognosis. This is irrespective of any
particular TMM but has prognostic significance when the group of
liposarcoma samples is considered as a whole, with the high hTR
expressing group including some ALT, Telþ and ALT /Tel 
samples. We are now beginning to gain some insight into the
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While the search continues for specific markers to define ALT and
to predict the clinical outcome in ALT associated tumours more
effectively, the data presented here provide a platform to define the
relationship between clinical outcome and the underlying biology
of telomere maintenance in cancer.
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